文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

序贯接种两种大流行前H5N1疫苗诱导持久异源抗体反应

Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines.
PubMed 文献 · Vaccine · 2020-11-24

本研究在成人中检测接种两种不同A(H5N1)疫苗前后的血清抗体。两剂AS03佐剂A/Indonesia/5/2005疫苗诱导良好的同源但较差的异源中和抗体反应;2011年非佐剂A/Vietnam/1203/2004加强接种则诱导非常强且持久的同源和异源抗体反应,支持在大流行准备中采用初免-加强策略。

要点

  • 两剂AS03佐剂A/Indonesia/5/2005疫苗同源反应好但异源反应差。
  • 非佐剂A/Vietnam/1203/2004加强接种诱导强且持久的交叉分支抗体。
  • 序贯接种两种大流行前H5N1疫苗支持初免-加强策略。

核心结论

  • 序贯接种两种不同A(H5N1)大流行前疫苗可诱导持久高水平跨分支免疫,支持大流行准备中的初免-加强策略。

研究设计与样本

  • 在成人中于2009年和2011年接种两种不同A(H5N1)疫苗前后,用ELISA为基础的中和试验和血凝抑制试验检测针对不同A(H5N1)分支病毒的血清抗体。

主要发现

  • 两剂AS03佐剂A/Indonesia/5/2005疫苗诱导良好的同源但较差的异源中和抗体反应。
  • 2011年非佐剂A/Vietnam/1203/2004加强接种诱导非常强且持久的同源和异源抗体反应。
  • 在未暴露个体中同源反应仍较弱。

临床怎么用

  • 大流行准备计划可考虑采用两种不同A(H5N1)疫苗序贯初免-加强策略以诱导跨分支免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Avian influenza A(H5N1) viruses have caused sporadic infections in humans and thus they pose a significant global health threat. Among symptomatic patients the case fatality rate has been ca. 50%. H5N1 viruses exist in multiple clades and subclades and several candidate vaccines have been developed to prevent A(H5N1) infection as a principal measure for preventing the disease. METHODS: Serum antibodies against various influenza A(H5N1) clade viruses were measured in adults by ELISA-based microneutralization and haemagglutination inhibition tests before and after vaccination with two different A(H5N1) vaccines in 2009 and 2011. RESULTS: Two doses of AS03-adjuvanted A/Indonesia/5/2005 vaccine induced good homologous but poor heterologous neutralizing antibody responses against different clade viruses. However, non-adjuvanted A/Vietnam/1203/2004 booster vaccination in 2011 induced very strong and long-lasting homologous and heterologous antibody responses while homologous response remained weak in naïve subjects. CONCLUSIONS: Sequential vaccination with two different A(H5N1) pre-pandemic vaccines induced long-lasting high level cross-clade immunity against influenza A(H5N1) strains, thus supporting a prime-boost vaccination strategy in pandemic preparedness plans.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haveri A, Ikonen N, Savolainen-Kopra C, et al. Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines. Vaccine. 2020. PMID: 33246672. doi:10.1016/j.vaccine.2020.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。